Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Bristol-Myers Squibb Company    BMY

BRISTOL-MYERS SQUIBB COMPANY (BMY)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Bristol Myers Squibb : Computational scientists design a new IL-2 cancer drug and spin it out into a biotech startup

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/12/2019 | 03:42am EST

One of the Holy Grails in the booming immuno-oncology research field right now involves finding an IL-2 drug that can be used safely and effectively to combat cancer, without the immense toxicity that has largely sidelined the original IL-2 Proleukin. Bristol-Myers Squibb paid Nektar $1.85 billion in upfront cash to partner on NKTR-214 which has since come under a cloud of uncertainty over flailing response rates in their key demonstration study combining it with Opdivo.

Now a group of scientists at the University of Washington says they built an IL-2 protein therapy all their own, and theyve launched a new biotech Neoleukin to take it forward from mouse studies toward the clinic.

Describing their work to a writer at UW Medicine, the group says they designed their protein to bind specifically to IL-2 beta and gamma receptors to whip up a more potent T cell response to cancer while steering clear of CD25 to circumvent the toxic reaction. By doing that they created a lab model of the drug that the scientists were able to ratchet up the dose on without the lethal reaction.

They also added a complementary component for IL-15 to increase the efficacy and dubbed the drug Neo-2/15, describing it as particularly small and stable. And the game plan is to continue to use their computational skills to improve the drug.

Neo-2/15 has therapeutic properties that are at least as good as or better than naturally occurring IL-2, but it was computationally designed to be much less toxic, said Umut Ulge, one of the lead authors of a paper published in Nature.

Neoleukin, though, is hardly the only rival to the throne that Nektar and Bristol-Myers Squibb have been striving for. Laura Shawvers Synthorx has also been angling for the clinic in H1 of this year with their drug candidate Synthorin IL-2, backed by Orbimed and Medicxi. The biotech $THOR went public just a few weeks ago, raising $150 million.

Last November Nektar Therapeutics $NKTR managed to add 1 more patient out of its 38 evaluable stage 4 melanoma patients to the win column with its closely-watched 3-month update on Opdivo/NKTR-214s objective response rate. That managed to nudge up the ORR from 50% a figure that routed Nektars stock at ASCO to 53%. But the scientists also pushed up the complete response rate to 24%, maintaining they were satisfied with the improved response they were seeing.

(c) 2019 Future Publishing Limited Quay House, The Ambury, Bath BA1 1UA. All rights reserved Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BRISTOL-MYERS SQUIBB COMPA
04:50aMSKCC says senior execs may not hold industry board seats
AQ
04:36aAscletis to develop Alphamab's PD-L1 antibody for HBV in China
AQ
01/14BRISTOL MYERS SQUIBB : EC Approves Opdivo Plus Yervoy for Some Patients with Ren..
DJ
01/14BRISTOL MYERS SQUIBB : European Commission Approves Opdivo (nivolumab) Plus Low-..
PU
01/12BRISTOL MYERS SQUIBB : Computational scientists design a new IL-2 cancer drug an..
AQ
01/10ONO PHARMACEUTICAL : Opdivo meets OS endpoint in esophageal cancer trial
AQ
01/08GlaxoSmithKline to look for early-stage assets - CEO
RE
01/08CELGENE INVESTOR ALERT BY THE FORMER : Kahn Swick & Foti, LLC Investigates Adequ..
PR
01/08SECOND BIG M&A DEAL OF 2019 : Lilly to acquire Loxo
AQ
01/08BRISTOL MYERS SQUIBB : Celgene executives whipped up new, lucrative severance pl..
AQ
More news
Financials ($)
Sales 2018 22 548 M
EBIT 2018 6 169 M
Net income 2018 5 190 M
Finance 2018 1 244 M
Yield 2018 3,42%
P/E ratio 2018 15,20
P/E ratio 2019 14,11
EV / Sales 2018 3,42x
EV / Sales 2019 3,09x
Capitalization 78 297 M
Chart BRISTOL-MYERS SQUIBB COMPANY
Duration : Period :
Bristol-Myers Squibb Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BRISTOL-MYERS SQUIBB COMPA
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 15
Average target price 58,3 $
Spread / Average Target 21%
EPS Revisions
Managers
NameTitle
Giovanni Caforio Chairman & Chief Executive Officer
Johanna Mercier President & Head-US Commercial
Charles A. Bancroft CFO, EVP & Head-Global Business Operations
Paul von Autenried Chief Information Officer & Senior Vice President
Thomas James Lynch Chief Scientific Officer & Executive VP
Sector and Competitors
1st jan.Capitalization (M$)
BRISTOL-MYERS SQUIBB COMPANY-7.71%78 297
JOHNSON & JOHNSON0.24%344 044
PFIZER-2.93%245 746
ROCHE HOLDING LTD.4.13%221 817
NOVARTIS1.59%221 313
MERCK AND COMPANY-2.50%190 790